Onconova Therapeutics Inc logo

Onconova Therapeutics Inc

FRA:0T2 (USA)  
€ 0.81 (+5.88%) Mar 27
At Loss
P/B:
1.40
Market Cap:
€ 18.81M ($ 20.29M)
Enterprise V:
€ -4.50M ($ -4.85M)
Volume:
-
Avg Vol (2M):
1.85K
Also Trade In:

Business Description

Onconova Therapeutics Inc logo
Onconova Therapeutics Inc
NAICS : 325412 SIC : 2834
ISIN : US68232V3069
Description
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.54
Interest Coverage No Debt
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -25.48
Distress
Grey
Safe
Beneish M-Score -3.68
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 57.87
9-Day RSI 56.26
14-Day RSI 57.07
12-1 Month Momentum % 4.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.79
Quick Ratio 2.79
Cash Ratio 2.61
Days Sales Outstanding 35.21

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -41.3

Financials (Next Earnings Date:2024-05-15 Est.)

FRA:0T2's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Onconova Therapeutics Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.211
EPS (TTM) (€) -0.908
Beta 1.21
Volatility % 68.57
14-Day RSI 57.07
14-Day ATR (€) 0.027904
20-Day SMA (€) 0.80175
12-1 Month Momentum % 4.74
52-Week Range (€) 0.56 - 1.27
Shares Outstanding (Mil) 21

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Onconova Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Onconova Therapeutics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Onconova Therapeutics Inc Frequently Asked Questions

What is Onconova Therapeutics Inc(FRA:0T2)'s stock price today?
The current price of FRA:0T2 is €0.81. The 52 week high of FRA:0T2 is €1.27 and 52 week low is €0.56.
When is next earnings date of Onconova Therapeutics Inc(FRA:0T2)?
The next earnings date of Onconova Therapeutics Inc(FRA:0T2) is 2024-05-15 Est..
Does Onconova Therapeutics Inc(FRA:0T2) pay dividends? If so, how much?
Onconova Therapeutics Inc(FRA:0T2) does not pay dividend.

Press Release

Subject Date
No Press Release